FLT3 and acute myeloid leukemia: The weighted mean FLT3‐ITD mutation prevalence estimated for this patient population was 20.4% (95% CI: 19.1%–21.8%), lower than the estimate referenced in several recent reviews of AML treatment (approximately 25.0%) [1, 2, 3].